诺瓦瓦克斯医药(NVAX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVAX 诺瓦瓦克斯医药

盘后交易 03-20 18:38:05 EDT

9.62

-0.12

-1.23%

盘后9.70

+0.08+0.83%

18:32 EDT

最高10.00	最低9.42	成交量568.33万
今开9.84	昨收9.74	日振幅5.95%
总市值15.63亿	流通市值13.15亿	总股本1.62亿
成交额5,512万	换手率4.16%	流通股本1.37亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVAX","market":"US","secType":"STK","nameCN":"诺瓦瓦克斯医药","latestPrice":9.62,"timestamp":1774036800000,"preClose":9.74,"halted":0,"volume":5683335,"hourTrading":{"tag":"盘后","latestPrice":9.7,"preClose":9.62,"latestTime":"18:32 EDT","volume":965180,"amount":9285258.417299999,"timestamp":1774045938946,"change":0.08,"changeRate":0.008316,"amplitude":0.021975},"delay":0,"changeRate":-0.012320328542094557,"floatShares":136723812,"shares":162498995,"eps":2.58,"marketStatus":"盘后交易","change":-0.12,"latestTime":"03-20 18:38:05 EDT","open":9.84,"high":10,"low":9.42,"amount":55123558.448594995,"amplitude":0.059548,"askPrice":9.72,"askSize":50,"bidPrice":9.25,"bidSize":11,"shortable":3,"etf":0,"ttmEps":2.58,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1774051200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":9.74,"preHourTrading":{"tag":"盘前","latestPrice":9.82,"preClose":9.74,"latestTime":"09:29 EDT","volume":21485,"amount":208555.81885500002,"timestamp":1774013399999,"change":0.08,"changeRate":0.008214,"amplitude":0.027721},"postHourTrading":{"tag":"盘后","latestPrice":9.7,"preClose":9.62,"latestTime":"18:32 EDT","volume":965180,"amount":9285258.417299999,"timestamp":1774045938946,"change":0.08,"changeRate":0.008316,"amplitude":0.021975},"volumeRatio":1.413752,"impliedVol":0.8568,"impliedVolPercentile":0.4582},"requestUrl":"/m/hq/s/NVAX","defaultTab":"news","newsList":[{"id":"1162099302","title":"诺瓦瓦克斯医药上调2026年调整后营收预期，受疫苗交易强劲表现提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1162099302","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162099302?lang=zh_cn&edition=full","pubTime":"2026-02-26 23:07","pubTimestamp":1772118465,"startTime":"0","endTime":"0","summary":"周四， $诺瓦瓦克斯医药$ 上调了其2026年调整后营收预测，称预计来自疫苗供应和授权协议的里程碑付款将抵消需求疲软带来的压力。这家生物科技公司目前预计，2026年调整后营收将在2.30亿美元至2.70亿美元之间，高于此前预计的1.85亿美元至2.05亿美元。Novavax预计将在2028年前实现盈利，主要受益于其与Sanofi合作协议中的关键产品上市，包括一款采用其Nuvaxovid疫苗的COVID-流感二联疫苗。受消息影响， $诺瓦瓦克斯医药$ 升19%。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"59d2b24cafa113cadc65f4c13bf874dc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"诺瓦瓦克斯医药上调2026年调整后营收预期，受疫苗交易强劲表现提振","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVAX"],"gpt_icon":1},{"id":"1191168252","title":"诺瓦瓦克斯医药CEO谈即将召开的CDC ACIP会议：“已确定召开，这是好消息，我们将密切关注”","url":"https://stock-news.laohu8.com/highlight/detail?id=1191168252","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191168252?lang=zh_cn&edition=full","pubTime":"2026-02-26 22:53","pubTimestamp":1772117621,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药首席执行官对即将举行的美国疾病控制与预防中心免疫实践咨询委员会会议发表评论，称会议日程已确定，这是一个积极信号，公司方面将予以高度关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4568","BK4585","NVAX","BK4547","BK4139"],"gpt_icon":0},{"id":"1193975080","title":"异动解读 | 诺瓦瓦克斯医药盘前大跌9.76%，CEO警告宏观与监管环境带来重大不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=1193975080","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193975080?lang=zh_cn&edition=full","pubTime":"2026-02-26 21:44","pubTimestamp":1772113479,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药(NVAX)今日盘前股价大跌9.76%，引发了市场关注。消息面上，公司首席执行官公开指出，美国当前面临的宏观经济形势与监管环境，正为疫苗企业带来显著的不确定性。这一表态直接加剧了投资者对于诺瓦瓦克斯医药未来运营压力与增长前景的担忧，可能是导致股价在盘前交易时段承压下跌的主要原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVAX"],"gpt_icon":0},{"id":"1123126799","title":"诺瓦瓦克斯医药CEO：美国当前宏观与监管环境为疫苗公司带来重大不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=1123126799","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123126799?lang=zh_cn&edition=full","pubTime":"2026-02-26 21:42","pubTimestamp":1772113334,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药首席执行官指出，美国当前面临的宏观经济形势与监管环境，正为疫苗企业带来显著的不确定性。这一表态凸显了行业在复杂外部环境下所承受的运营压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4568","BK4547","NVAX","BK4585"],"gpt_icon":0},{"id":"2606775920","title":"诺瓦瓦克斯医药盘中异动 早盘大幅拉升5.09%报10.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606775920","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606775920?lang=zh_cn&edition=full","pubTime":"2026-01-27 22:46","pubTimestamp":1769525177,"startTime":"0","endTime":"0","summary":"北京时间2026年01月27日22时46分，诺瓦瓦克斯医药股票出现异动，股价大幅拉升5.09%。截至发稿，该股报10.12美元/股，成交量112.865万股，换手率0.69%，振幅4.05%。诺瓦瓦克斯医药股票所在的生物技术行业中，整体涨幅为0.94%。其相关个股中，Biomx Inc.、阿诺医药、Acumen Pharmaceuticals, Inc.涨幅较大，Biomx Inc.、Vyome Holdings, Inc.、Genenta Science Spa较为活跃，换手率分别为756.87%、687.03%、215.81%，振幅较大的相关个股有Biomx Inc.、Genenta Science Spa、Kazia Therapeutics Limited，振幅分别为53.90%、25.38%、21.94%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012722461797a3a3c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012722461797a3a3c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVAX","BK4139","BK4568","BK4585","BK4588","BK4547"],"gpt_icon":0},{"id":"2604147291","title":"诺瓦瓦克斯（Novavax）股价上涨3.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604147291","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604147291?lang=zh_cn&edition=full","pubTime":"2026-01-20 22:57","pubTimestamp":1768921028,"startTime":"0","endTime":"0","summary":"每经AI快讯，1月20日，诺瓦瓦克斯（Novavax）与辉瑞（Pfizer）签署疫苗研发许可协议后，其股价上涨3.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601203625027339.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601203625027339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NVAX","BK4547","BK4139","BK4588","BK4585","BK4568"],"gpt_icon":0},{"id":"2605108778","title":"诺瓦瓦克斯医药与辉瑞达成非独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2605108778","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605108778?lang=zh_cn&edition=full","pubTime":"2026-01-20 21:56","pubTimestamp":1768917360,"startTime":"0","endTime":"0","summary":"1月20日消息，诺瓦瓦克斯医药与辉瑞达成非独家许可协议，允许辉瑞在多达两个疾病领域应用诺瓦瓦克斯医药的Matrix-M佐剂，该佐剂可增强疫苗免疫反应。通过此次合作，诺瓦瓦克斯医药不仅将获得3000万美元的预付款，后续还有机会根据开发和销售情况，额外获得最高达5亿美元的里程碑付款。此次合作有望推动疫苗研发创新，为全球公共卫生事业带来积极影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120215811a44166bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120215811a44166bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BLSP4452.SGD","LU0985481810.HKD","LU1066051498.USD","LU0321505868.SGD","LU0122379950.USD","BK4550","BK4588","BK4534","LU0868494617.USD","LU0058720904.USD","BK4568","IE00B19Z3B42.SGD","PFE","IE000M9KFDE8.USD","LU0321505439.SGD","LU0289739699.SGD","BK4599","LU0306807586.USD","LU1057294990.SGD","BK4007","LU0170899867.USD","LU0225771236.USD","LU0234572021.USD","IE00B19Z3581.USD","NVAX","SG9999002232.USD","IE00BBT3K403.USD","SG9999001176.SGD","LU1894683264.USD","BK4533","LU1023059063.AUD","SG9999013999.USD","IE0002270589.USD","BK4547","LU0225284248.USD","LU1894683348.USD","SGXZ57979304.SGD","SG9999001176.USD","SG9999002224.SGD","BK4139","SG9999011175.SGD","BK4592","LU0306806265.USD","LU1883839398.USD","LU1066053197.SGD","BK4581","LU0456855351.SGD","IE00BLSP4239.USD","BK4585","SG9999003800.SGD"],"gpt_icon":0},{"id":"1100905300","title":"异动解读 | 辉瑞主导含佐剂产品事务，诺瓦瓦克斯医药盘前大涨7.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100905300","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100905300?lang=zh_cn&edition=full","pubTime":"2026-01-20 20:08","pubTimestamp":1768910899,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药（NVAX）今日盘前股价大涨7.12%，市场反应积极。消息面上，诺瓦瓦克斯医药宣布其合作伙伴辉瑞将全面掌控含佐剂产品的研发、制造及商业化决策权。这一合作条款意味着辉瑞在项目中获得了主导地位，可能为诺瓦瓦克斯医药带来战略优势，包括减轻运营负担或增强商业化能力，从而提振了投资者信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVAX"],"gpt_icon":0},{"id":"1107422362","title":"诺瓦瓦克斯医药：辉瑞将主导含佐剂产品的开发、生产与商业化事务","url":"https://stock-news.laohu8.com/highlight/detail?id=1107422362","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107422362?lang=zh_cn&edition=full","pubTime":"2026-01-20 20:07","pubTimestamp":1768910863,"startTime":"0","endTime":"0","summary":"根据最新协议安排，诺瓦瓦克斯医药（Novavax）宣布，其合作伙伴辉瑞（Pfizer）将全面掌控涉及含佐剂产品的研发、制造及商业化相关决策权。这一关键条款意味着辉瑞在合作项目中获得了主导地位，将对未来产品线的战略方向产生决定性影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BBT3K403.USD","LU0289739699.SGD","SGXZ57979304.SGD","IE0002270589.USD","IE00BLSP4239.USD","NVAX","SG9999002232.USD","LU0122379950.USD","LU0985481810.HKD","IE00B19Z3581.USD","BK4007","BK4592","LU0306806265.USD","SG9999001176.SGD","IE000M9KFDE8.USD","IE00BLSP4452.SGD","BK4588","SG9999003800.SGD","LU1023059063.AUD","SG9999013999.USD","LU0058720904.USD","LU0225284248.USD","LU0321505868.SGD","LU1883839398.USD","SG9999002224.SGD","LU1066053197.SGD","BK4585","BK4581","LU1066051498.USD","BK4568","LU1057294990.SGD","BK4599","LU1894683264.USD","BK4550","BK4139","BK4533","BK4547","LU0868494617.USD","LU0225771236.USD","SG9999011175.SGD","SG9999001176.USD","PFE","LU0234572021.USD","IE00B19Z3B42.SGD","LU0321505439.SGD","LU1894683348.USD","BK4534","LU0170899867.USD","LU0456855351.SGD","LU0306807586.USD"],"gpt_icon":0},{"id":"2603578019","title":"诺瓦瓦克斯医药盘中异动，股价大涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603578019","media":"市场透视","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603578019?lang=zh_cn&edition=full","pubTime":"2026-01-13 02:54","pubTimestamp":1768244079,"startTime":"0","endTime":"0","summary":"是一家从事疫苗开发的生物技术公司。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113025439953c74c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113025439953c74c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVAX"],"gpt_icon":0},{"id":"2601282749","title":"诺瓦瓦克斯医药盘中异动 急速拉升5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601282749","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601282749?lang=zh_cn&edition=full","pubTime":"2026-01-06 22:46","pubTimestamp":1767710786,"startTime":"0","endTime":"0","summary":"北京时间2026年01月06日22时46分，诺瓦瓦克斯医药股票出现异动，股价快速上涨5.10%。截至发稿，该股报7.62美元/股，成交量50.1334万股，换手率0.31%，振幅5.24%。机构评级方面，在所有10家参与评级的机构中，50%的券商给予买入建议，20%的券商给予持有建议，30%的券商给予卖出建议。诺瓦瓦克斯医药股票所在的生物技术行业中，整体涨幅为1.50%。诺瓦瓦克斯医药公司简介：诺瓦瓦克斯医药公司是一家从事疫苗开发的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106224626a4a3dfb9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106224626a4a3dfb9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVAX","BK4547","BK4139","BK4585","BK4588","BK4568"],"gpt_icon":0},{"id":"1199033044","title":"美股异动 | 疫苗股下跌，Moderna跌超6%！FDA提及儿童死亡与新冠疫苗关联","url":"https://stock-news.laohu8.com/highlight/detail?id=1199033044","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199033044?lang=zh_cn&edition=full","pubTime":"2025-12-01 23:26","pubTimestamp":1764602786,"startTime":"0","endTime":"0","summary":"12月1日，部分美股疫苗股盘中下跌，$Moderna(MRNA)$跌超6%，$诺瓦瓦克斯(NVAX)$跌近4%，$BioNTech(BNTX)$跌超3%。此前$美国食品(USFD)$药物管理局备忘录提及儿童死亡与新冠疫苗的关联。","market":"us","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f5a0c542474fbfdd95db309645c9c3a7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA","BNTX","NVAX"],"gpt_icon":0},{"id":"1111401391","title":"诺瓦瓦克斯医药 - FDA批准将Nuvaxovid授权转移至赛诺菲 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1111401391","media":"投资观察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111401391?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:33","pubTimestamp":1763570005,"startTime":"0","endTime":"0","summary":"11月4日 - 诺瓦瓦克斯医药公司公告：FDA已批准将Nuvaxovid的授权转移至赛诺菲。根据SEC文件，Nuvaxovid的市场授权转移将促使赛诺菲向诺瓦瓦克斯支付2500万美元。诺瓦瓦克斯预计将在2026年第一季度收到赛诺菲的里程碑付款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4139","BK4547","BK4568","NVAX"],"gpt_icon":0},{"id":"2583533998","title":"股东敦促诺瓦瓦克斯医药进行战略调整，警告称或考虑发起代理权争夺战","url":"https://stock-news.laohu8.com/highlight/detail?id=2583533998","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583533998?lang=zh_cn&edition=full","pubTime":"2025-11-13 09:56","pubTimestamp":1762998969,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4139","BK4568","BK4588","BK4585","BK4547","NVAX"],"gpt_icon":0},{"id":"1111971531","title":"Shah Capital：“诺瓦瓦克斯医药的股东更应在一家更大且更有能力的制药公司旗下获得服务”","url":"https://stock-news.laohu8.com/highlight/detail?id=1111971531","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111971531?lang=zh_cn&edition=full","pubTime":"2025-11-13 05:20","pubTimestamp":1762982419,"startTime":"0","endTime":"0","summary":"Shah Capital：“诺瓦瓦克斯医药的股东更应在一家更大且更有能力的制药公司旗下获得服务”","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4547","BK4139","NVAX","BK4588","BK4585"],"gpt_icon":0},{"id":"2582348679","title":"B. Riley下调诺瓦瓦克斯医药目标价至16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582348679","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582348679?lang=zh_cn&edition=full","pubTime":"2025-11-12 11:24","pubTimestamp":1762917849,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["NVAX","BK4568","BK4547","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"1169223015","title":"诺瓦瓦克斯医药高管表示，预计2026-27赛季Nuvaxovid的版税将显著增长，与2025年相比","url":"https://stock-news.laohu8.com/highlight/detail?id=1169223015","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169223015?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:06","pubTimestamp":1762437990,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药高管表示，预计2026-27赛季Nuvaxovid的版税将显著增长，与2025年相比","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4568","NVAX","BK4585","BK4547","BK4139"],"gpt_icon":0},{"id":"1159594138","title":"异动解读 | 诺瓦瓦克斯医药盘前大涨5.85%，季度收入超出预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1159594138","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159594138?lang=zh_cn&edition=full","pubTime":"2025-11-06 21:06","pubTimestamp":1762434403,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药（Novavax，股票代码：NVAX）今日盘前大涨5.85%，引起投资者关注。这一显著涨幅主要源于公司公布的第三季度财报超出市场预期。\n\n根据最新公布的财务报告，诺瓦瓦克斯第三季度总营收达到7040万美元，远超分析师平均预期的4213万美元。公司表示，这一亮眼业绩主要得益于与新冠疫苗合作相关的里程碑付款。\n\n作为一家生物技术公司，诺瓦瓦克斯此次超出预期的财务表现显示了其在新冠疫苗领域的持续影响力。这一业绩不仅反映了公司当前的经营状况，还可能预示着其未来在疫苗研发和商业化方面的潜力。投资者对这一积极信号做出了正面反应，推动了股价的大幅上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVAX"],"gpt_icon":0},{"id":"1109168706","title":"诺瓦瓦克斯医药完成Nuvaxovid™在美国的市场授权转让给赛诺菲，触发2500万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1109168706","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109168706?lang=zh_cn&edition=full","pubTime":"2025-11-04 20:00","pubTimestamp":1762257635,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药完成Nuvaxovid™在美国的市场授权转让给赛诺菲，触发2500万美元里程碑付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVAX","BK4568","BK4547","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"1134584006","title":"诺瓦瓦克斯医药：设施租约转让及某些相关资产出售将使公司获得4000万美元付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1134584006","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134584006?lang=zh_cn&edition=full","pubTime":"2025-10-22 19:03","pubTimestamp":1761130981,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药：设施租约转让及某些相关资产出售将使公司获得4000万美元付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVAX","BK4585","BK4547","BK4588","BK4568","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novavax.com","stockEarnings":[{"period":"1week","weight":-0.0544},{"period":"1month","weight":0.126},{"period":"3month","weight":0.4625},{"period":"6month","weight":0.1183},{"period":"1year","weight":0.2314},{"period":"ytd","weight":0.4494}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.0305},{"period":"6month","weight":-0.0059},{"period":"1year","weight":0.1634},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novavax, Inc.于1987年根据美国特拉华州法律注册成立，是一家临床阶段的生物制药公司，专注于重组纳米颗粒疫苗和佐剂的发现、开发和商业化。该公司的疫苗技术平台基于包括病毒样颗粒（VLP）和蛋白质纳米颗粒候选疫苗的专有重组纳米颗粒疫苗技术。该公司的候选疫苗是基因工程的三维纳米结构，其中包含了免疫学上重要的蛋白质。公司的疫苗产品管线针对多种传染病，候选药物目前处于呼吸道合胞病毒（RSV）、季节性流感、大流行性流感的临床开发阶段。此外，该公司在印度的合资公司CPL Biologics Private Limited（CPLB）正在积极开发多款候选疫苗，这些候选疫苗由诺瓦瓦克斯医药进行基因工程改造。","yearOnYearQuotes":[{"month":1,"riseRate":0.677419,"avgChangeRate":0.108114},{"month":2,"riseRate":0.580645,"avgChangeRate":0.042802},{"month":3,"riseRate":0.258065,"avgChangeRate":-0.040858},{"month":4,"riseRate":0.466667,"avgChangeRate":0.00903},{"month":5,"riseRate":0.533333,"avgChangeRate":0.126007},{"month":6,"riseRate":0.5,"avgChangeRate":0.090368},{"month":7,"riseRate":0.566667,"avgChangeRate":0.019422},{"month":8,"riseRate":0.533333,"avgChangeRate":0.039885},{"month":9,"riseRate":0.5,"avgChangeRate":-0.036425},{"month":10,"riseRate":0.3,"avgChangeRate":0.027361},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.003351},{"month":12,"riseRate":0.366667,"avgChangeRate":-0.038609}],"exchange":"NASDAQ","name":"诺瓦瓦克斯医药","nameEN":"Novavax"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺瓦瓦克斯医药(NVAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺瓦瓦克斯医药(NVAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺瓦瓦克斯医药,NVAX,诺瓦瓦克斯医药股票,诺瓦瓦克斯医药股票老虎,诺瓦瓦克斯医药股票老虎国际,诺瓦瓦克斯医药行情,诺瓦瓦克斯医药股票行情,诺瓦瓦克斯医药股价,诺瓦瓦克斯医药股市,诺瓦瓦克斯医药股票价格,诺瓦瓦克斯医药股票交易,诺瓦瓦克斯医药股票购买,诺瓦瓦克斯医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺瓦瓦克斯医药(NVAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺瓦瓦克斯医药(NVAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}